Evidence map›Paper›PMID 40163303›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

High-Content Imaging-Based Screening for Anticancer Compounds in Zebrafish Xenografts.

Caterina Sturtzel, Sarah Grissenberger, Andrea Wenninger-Weinzierl, Martin Distel

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Caterina SturtzelSt. Anna Children's Cancer Research Institute, Vienna, Austria.
Sarah GrissenbergerSt. Anna Children's Cancer Research Institute, Vienna, Austria.
Andrea Wenninger-WeinzierlSt. Anna Children's Cancer Research Institute, Vienna, Austria.
Martin DistelSt. Anna Children's Cancer Research Institute, Vienna, Austria. martin.distel@hci.utah.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Larval zebrafish xenografts are a vertebrate model system suited for screening small compounds towards their anticancer effects. The small size and transparency of zebrafish larvae allow for phenotypic screening in 96-well format. Due to the achievable throughput in a living vertebrate organism, zebrafish xenografts promise to bridge the gap between in vitro screening and testing compounds in mouse xenografts. Here, we describe a workflow for establishing xenografts in zebrafish embryos/larvae for subsequent automated high-content imaging-based screening of small compounds.

Indexed as

Antineoplastic AgentsHigh-Throughput Screening AssaysXenograft Model Antitumor AssaysZebrafishAnimalsDrug Screening Assays, AntitumorEmbryo, NonmammalianHumansLarvaAntineoplastic AgentsHigh-content imagingLarval zebrafish xenograftsSmall compound screeningTumor cells

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.